ClinicalTrials.gg
RecruitingNCT07083388Updated Jul 24, 2025

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)

A Phase 1 interventional study of Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg and Dapagliflozin 10 mg in Diabetes Mellitus, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing dapagliflozin in Diabetes Mellitus — 8 open to participants now, 10 under way, 4 of them phase 3. dapagliflozin · Diabetes Mellitus.

Planned enrollment
37th of 51
52 · median 80
Started
2025
with 1 other
Phase 1
7 of 51
2 open now
Registered
49th of 51
by date
Lead sponsor
3 of 51
Boryung Pharmaceutical Co., Ltd

Among the 51 studies testing dapagliflozin in Diabetes Mellitus, this one is the 37th largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 1, and was the 49th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

8 of the 51 studies testing dapagliflozin in Diabetes Mellitus are open now, in 7 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing dapagliflozin in Diabetes Mellitus, or all of them as a file.
02

Study summary

This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B," and "BR3006C" in healthy adult volunteers.

Read the detailed description

A total of 52 healthy volunteers will be enrolled to evaluate the pharmacokinetics and safety profiles of the study drug (one combination tablet of dapagliflozin 10 mg/pioglitazone 30 mg/metformin HCl 1000 mg) and the comparator (co-administration of dapagliflozin 10 mg, pioglitazone 30 mg, and metformin HCl 1000 mg, one tablet each, respectively) while fasting.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • Dapagliflozin
  • Pioglitazone
  • Metformin HCl
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged over 19 at the time of consent
  • Those who are eligible to participate in the clinical trial at the discretion of the principal investigator (or a subinvestigator) through laboratory tests such as hematology tests, blood chemistry tests, serology tests, urine tests, and (ECG) tests that were planned/performed with specification to the product.
  • Those who provided written consent after receiving sufficient explanations and fully understood the objective and details of this clinical trial, the characteristics of the investigational product, and the expected adverse events.

Exclusion criteria

Exclusion Criteria:

  • Those who have administered products within 6 months from the first dose administration date in another clinical trial (including bioequivalent studies) (The end of study date is based on the last dose administration date.)
  • Those who have undergone gastrointestinal surgeries or have gastrointestinal diseases (except appendectomy or hernia surgery) that may affect the absorption of the investigational products
  • Those who are pregnant, suspected of pregnancy, or nursing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Sequence A (R1+R2+R3 / T)

    R1+R2+R3: BR3006A, BR3006B, and BR3006C; T: BR3006

    Drug: Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg · Drug: Dapagliflozin 10 mg · Drug: Pioglitazone 30 mg · Drug: Metformin HCl 1000 mg

  • Experimental
    Sequence B (T / R1+R2+R3)

    T: BR3006; R1+R2+R3: BR3006A, BR3006B, and BR3006C

    Drug: Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg · Drug: Dapagliflozin 10 mg · Drug: Pioglitazone 30 mg · Drug: Metformin HCl 1000 mg

Interventions

  • DrugDapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg

    Drug page: Dapagliflozin

    Orally administered once per day

    Also known as: BR3006

  • Orally administered once per day

    Also known as: BR3006A

  • Orally administered once per day

    Also known as: BR3006B

  • Orally administered once per day

    Also known as: BR3006C

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic variable - Cmax

    Maximum plasma concentration of "BR3006" and "BR3006A," "BR3006B," and "BR3006C"

    Time frame: From Day 1, 0 hour (pre-dose) to Day 5 after dose administration

  2. Pharmacokinetic variable - AUCt

    Area under the drug concentration-time curve over the time interval of "BR3006" and "BR3006A," "BR3006B," and "BR3006C"

    Time frame: From Day 1, 0 hour (pre-dose) to Day 5 after dose administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2026, 12 months after the start.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 12 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jul 24, 2025
StartActual
Jul 3, 2025
Primary completionEst.
Jul 3, 2026
CompletionEst.
Jul 3, 2026
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07083388
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Jul 3, 2025
Primary completion
Jul 3, 2026 (estimated)
Completion
Jul 3, 2026 (estimated)
Last update
Jul 24, 2025

Study contacts

Shinyoung Oh
Contact
syoh@boryung.co.kr
+82 2-708-8000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Pioglitazone · Metformin

Start the discussion